冠状动脉粥样硬化PCI术后临床用药分析  

Analysis of clinical drug use in coronary atherosclerosis after PCI

作　　者：曾繁涛[1] 陈旎旎 李成[1] 姚苑梅[1] 张文[2] 

机构地区：[1]深圳市第四人民医院,广东深圳518033 [2]广东药学院,广东广州510006

出　　处：《现代医药卫生》2010年第17期2567-2568,共2页Journal of Modern Medicine & Health

摘　　要：目的:分析冠状动脉粥样硬化经皮冠状动脉支架置入术(PCI)手术后用药情况,为临床合理用药提供参考依据。方法:回顾性分析2003年～2009年冠状动脉粥样硬化PCI手术治疗患者的病历502例,通过拟定若干指标(年龄、体质量、血脂、病变部位、用药情况等)对进行统计分析。结果:发病年龄在28～92岁之间,男376例,女126例,其中50～70岁发病率最高,占82.13%;冠状动脉粥样硬化危险因素中高血压、高血脂、糖尿病各占63.17%、53.98%和31.27%;PCI术后再狭窄96例,占19.12%;PCI术后均使用抗血小板药物,并与抗高血压类、调血脂类等药物合用。结论:该院PCI术后临床用药状况基本合理。Objective：To analyze the drug use of coronary atherosclerosis after percutaneous coronary stent implantation （PCI） in order to provide reference basis for clinical rational drug use. Methods：The retrospective analysis on the medical records of 502 cases of coronary atherosclerosis treated with PCI surgical treatment between 2003～2009 was conducted. The indicators including age,weight,blood lipids,lesion location,drug use,etc. were statistically analyzed. Results：The age of onset was between 28～92 years old,376 males and 126 females;50～70 years of age had the highest incidence,accounting for 82.13%;in coronary atherosclerosis risk factors,hypertension,hyperlipidemia and diabetes accounted for 63.17%,53.98% and 31.27% respectively;96 cases of post-PCI restenosis accounted for 19.12%;anti-platelet drugs were used in all patients after PCI and were used in combination with antihypertensive and adjusting blood lipid drugs. Conclusion：The clinical drug use after PCI in our hospital is basically reasonable.

关 键 词：冠状动脉粥样硬化 PCI 危险因素 临床用药分析 

分 类 号：R5[医药卫生—内科学]